TWI794214B - 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物 - Google Patents

包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物 Download PDF

Info

Publication number
TWI794214B
TWI794214B TW107107838A TW107107838A TWI794214B TW I794214 B TWI794214 B TW I794214B TW 107107838 A TW107107838 A TW 107107838A TW 107107838 A TW107107838 A TW 107107838A TW I794214 B TWI794214 B TW I794214B
Authority
TW
Taiwan
Prior art keywords
brigatinib
pharmaceutical composition
lozenge
phenyl
pharmaceutical
Prior art date
Application number
TW107107838A
Other languages
English (en)
Chinese (zh)
Other versions
TW201840320A (zh
Inventor
東塔爾 S 薇薇傑思
薩米爾 廸薩
普來廸 K 雪爾瑪
理歐那德 W 羅薩慕思
傑夫 威廉森
丹尼卡 卡特萊特
帕萊吉 維德
Original Assignee
日商武田藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商武田藥品工業股份有限公司 filed Critical 日商武田藥品工業股份有限公司
Publication of TW201840320A publication Critical patent/TW201840320A/zh
Application granted granted Critical
Publication of TWI794214B publication Critical patent/TWI794214B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107107838A 2017-03-08 2018-03-08 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物 TWI794214B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762468696P 2017-03-08 2017-03-08
US62/468,696 2017-03-08
US201762491179P 2017-04-27 2017-04-27
US62/491,179 2017-04-27
US201762569954P 2017-10-09 2017-10-09
US62/569,954 2017-10-09

Publications (2)

Publication Number Publication Date
TW201840320A TW201840320A (zh) 2018-11-16
TWI794214B true TWI794214B (zh) 2023-03-01

Family

ID=61750531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107107838A TWI794214B (zh) 2017-03-08 2018-03-08 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物

Country Status (7)

Country Link
US (5) US20180256610A1 (https=)
EP (1) EP3592338A1 (https=)
JP (2) JP2020510027A (https=)
CN (1) CN110520110A (https=)
CA (1) CA3055109A1 (https=)
TW (1) TWI794214B (https=)
WO (1) WO2018165145A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094079A1 (en) * 2018-03-19 2019-09-26 Ariad Pharmaceuticals, Inc. Methods of treating cancer in pediatric patients
PH12022552454A1 (en) * 2020-04-14 2024-02-05 Janssen Biotech Inc Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
EP4306115A4 (en) * 2021-07-05 2024-11-20 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition, and preparation method therefor and application thereof
CN116407512A (zh) * 2021-12-31 2023-07-11 南京艾德凯腾生物医药有限责任公司 一种布格替尼冻干口崩片及其制备方法
CN115154473A (zh) * 2022-08-04 2022-10-11 中国人民解放军陆军特色医学中心 布格替尼作为axl、c-met、st3gal4抑制剂的新应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
WO2016065028A1 (en) * 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
WO2010092260A2 (fr) * 2009-02-13 2010-08-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate
US8691281B2 (en) * 2009-02-13 2014-04-08 Ipsen Pharma S.A.S. Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof
BR112013008816A2 (pt) * 2010-10-14 2016-06-28 Ariad Pharma Inc método de tratamento de câncer direcionado ao egfr resistente à erlotinibe ou gefitinibe, ou uso de um sal farmacêuticamente aceito em um indivíduo
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
LT2753312T (lt) * 2011-09-08 2017-01-25 Mereo Biopharma 2 Limited Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui
AU2012339753A1 (en) * 2011-11-14 2014-06-19 Tesaro, Inc. Modulating certain tyrosine kinases
US20140351963A1 (en) * 2011-12-10 2014-11-27 Ohio State Innovation Foundation MiRNAs Useful to Reduce Lung Cancer Tumorigenesis and Chemotherapy Resistance and Related Compositions and Methods
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
CN105073116A (zh) * 2013-03-14 2015-11-18 辉瑞大药厂 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
US9474761B2 (en) * 2014-06-10 2016-10-25 The George Washington University Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugs
CN105061506B (zh) * 2015-07-27 2017-08-29 苏州明锐医药科技有限公司 抗肿瘤药物ap26113的制备方法
US10813935B2 (en) * 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
WO2016065028A1 (en) * 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine

Also Published As

Publication number Publication date
US20210186994A1 (en) 2021-06-24
EP3592338A1 (en) 2020-01-15
US20240082275A1 (en) 2024-03-14
CA3055109A1 (en) 2018-09-13
JP2023027312A (ja) 2023-03-01
US20210401860A1 (en) 2021-12-30
US20180256610A1 (en) 2018-09-13
JP2020510027A (ja) 2020-04-02
CN110520110A (zh) 2019-11-29
TW201840320A (zh) 2018-11-16
WO2018165145A1 (en) 2018-09-13
US20220249524A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP6560289B2 (ja) 新たな医薬組成物
TWI794214B (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
JP6396980B2 (ja) ベンダムスチンの固体投与剤
TWI428151B (zh) 含有甘露醇或乳糖之固形製劑
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
TW201442712A (zh) 有機化合物之調配物
JP2025120468A (ja) イストラデフィリン製剤
JP2025016576A (ja) Ｔｌｒ７アゴニストを含む固体医薬組成物
EA027641B1 (ru) Продукт сомикронизации, включающий ацетат улипристала
EP2672959A1 (en) Granulated composition comprising tadalafil and a disintegrant
WO2022042646A1 (zh) 盐酸鲁拉西酮组合物及其制备方法
HK40017242A (en) Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
WO2014157603A1 (ja) 経口投与用医薬組成物
TWI746418B (zh) 包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇鈉之醫藥劑型
WO2019200512A1 (zh) 一种抗凝剂的速释药物制剂及其制备方法
TW202404585A (zh) 含有匹密特匹（Pimitespib）之醫藥組合物
JP2025018790A (ja) トファシチニブを含有するフィルムコーティング錠剤
HK40060520B (zh) 一种tlr7激动剂的固体药物组合物
HK40060520A (en) Solid pharmaceutical composition comprising tlr7 agonist
HK40105586A (zh) 包含依那格列净的药物组合物
HK40025159B (en) Orally administrable enzalutamide-containing pharmaceutical composition
HK1242993A1 (en) A pharmaceutical composition in a solid dosage form suitable for oral administration
HK1161089A (en) Solid dosage forms of bendamustine
HK1161089B (en) Solid dosage forms of bendamustine